Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles

Tatsuya Murakami, Wassana Wijagkanalan, Mitsuru Hashida, Kunihiro Tsuchida

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aim: Nascent high-density lipoprotein (HDL) capable of intracellularly delivering anticancer drugs was developed to potentiate antitumor activities. Materials & methods: Apolipoprotein A-I, a major component protein of HDL, was genetically fused to TAT peptide, a protein transduction domain. Nascent HDL was prepared with this mutant and phospholipids. Results & discussion: Intracellular delivery of doxorubicin (DXR) by TAT-fused HDL was confirmed by confocal microscopy. Treatment of cancer cells with TAT-fused HDL-DXR complex resulted in enhanced growth inhibition. Furthermore, TAT-fused HDL-DXR complex suppressed tumor growth in mice more efficiently than HDL-DXR complex. No bodyweight loss was observed for the TAT complex. These results clearly demonstrate the usefulness of TAT fusion to nascent HDL to potentiate the antitumor activity of DXR. Conclusion: The genetic fusion of apoA-I with biologically active peptides potentially enables a simple assembly of biocompatible and versatile drug carriers.

Original languageEnglish
Pages (from-to)867-879
Number of pages13
JournalNanomedicine
Volume5
Issue number6
DOIs
Publication statusPublished - 01-08-2010

Fingerprint

Lipoproteins
HDL Lipoproteins
Drug delivery
Nanoparticles
drug
Doxorubicin
Pharmaceutical Preparations
cancer
Apolipoprotein A-I
peptide
Peptides
Fusion reactions
Proteins
Drug Carriers
protein
nanoparticle
Confocal microscopy
Phospholipids
Growth
phospholipid

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Cite this

Murakami, Tatsuya ; Wijagkanalan, Wassana ; Hashida, Mitsuru ; Tsuchida, Kunihiro. / Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles. In: Nanomedicine. 2010 ; Vol. 5, No. 6. pp. 867-879.
@article{9954de0caf884a73a74517fdcc36f9ec,
title = "Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles",
abstract = "Aim: Nascent high-density lipoprotein (HDL) capable of intracellularly delivering anticancer drugs was developed to potentiate antitumor activities. Materials & methods: Apolipoprotein A-I, a major component protein of HDL, was genetically fused to TAT peptide, a protein transduction domain. Nascent HDL was prepared with this mutant and phospholipids. Results & discussion: Intracellular delivery of doxorubicin (DXR) by TAT-fused HDL was confirmed by confocal microscopy. Treatment of cancer cells with TAT-fused HDL-DXR complex resulted in enhanced growth inhibition. Furthermore, TAT-fused HDL-DXR complex suppressed tumor growth in mice more efficiently than HDL-DXR complex. No bodyweight loss was observed for the TAT complex. These results clearly demonstrate the usefulness of TAT fusion to nascent HDL to potentiate the antitumor activity of DXR. Conclusion: The genetic fusion of apoA-I with biologically active peptides potentially enables a simple assembly of biocompatible and versatile drug carriers.",
author = "Tatsuya Murakami and Wassana Wijagkanalan and Mitsuru Hashida and Kunihiro Tsuchida",
year = "2010",
month = "8",
day = "1",
doi = "10.2217/nnm.10.66",
language = "English",
volume = "5",
pages = "867--879",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "6",

}

Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles. / Murakami, Tatsuya; Wijagkanalan, Wassana; Hashida, Mitsuru; Tsuchida, Kunihiro.

In: Nanomedicine, Vol. 5, No. 6, 01.08.2010, p. 867-879.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles

AU - Murakami, Tatsuya

AU - Wijagkanalan, Wassana

AU - Hashida, Mitsuru

AU - Tsuchida, Kunihiro

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Aim: Nascent high-density lipoprotein (HDL) capable of intracellularly delivering anticancer drugs was developed to potentiate antitumor activities. Materials & methods: Apolipoprotein A-I, a major component protein of HDL, was genetically fused to TAT peptide, a protein transduction domain. Nascent HDL was prepared with this mutant and phospholipids. Results & discussion: Intracellular delivery of doxorubicin (DXR) by TAT-fused HDL was confirmed by confocal microscopy. Treatment of cancer cells with TAT-fused HDL-DXR complex resulted in enhanced growth inhibition. Furthermore, TAT-fused HDL-DXR complex suppressed tumor growth in mice more efficiently than HDL-DXR complex. No bodyweight loss was observed for the TAT complex. These results clearly demonstrate the usefulness of TAT fusion to nascent HDL to potentiate the antitumor activity of DXR. Conclusion: The genetic fusion of apoA-I with biologically active peptides potentially enables a simple assembly of biocompatible and versatile drug carriers.

AB - Aim: Nascent high-density lipoprotein (HDL) capable of intracellularly delivering anticancer drugs was developed to potentiate antitumor activities. Materials & methods: Apolipoprotein A-I, a major component protein of HDL, was genetically fused to TAT peptide, a protein transduction domain. Nascent HDL was prepared with this mutant and phospholipids. Results & discussion: Intracellular delivery of doxorubicin (DXR) by TAT-fused HDL was confirmed by confocal microscopy. Treatment of cancer cells with TAT-fused HDL-DXR complex resulted in enhanced growth inhibition. Furthermore, TAT-fused HDL-DXR complex suppressed tumor growth in mice more efficiently than HDL-DXR complex. No bodyweight loss was observed for the TAT complex. These results clearly demonstrate the usefulness of TAT fusion to nascent HDL to potentiate the antitumor activity of DXR. Conclusion: The genetic fusion of apoA-I with biologically active peptides potentially enables a simple assembly of biocompatible and versatile drug carriers.

UR - http://www.scopus.com/inward/record.url?scp=77956104719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956104719&partnerID=8YFLogxK

U2 - 10.2217/nnm.10.66

DO - 10.2217/nnm.10.66

M3 - Article

C2 - 20735223

AN - SCOPUS:77956104719

VL - 5

SP - 867

EP - 879

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 6

ER -